@article{MTMT:34802682,
	title = {Competing‐risks model for predicting the prognosis of patients with regressive melanoma based on the SEER database},
	url = {https://m2.mtmt.hu/api/publication/34802682},
	author = {Huang, Chaodi and Huang, Liying and Huang, Jianguo and Zheng, Xinkai and Jiang, Congjun and Tom, Kong Ching and Wu, U. Tim and Huang, WenHsien Ethan and Gao, Yunfei and Situ, Fangmin and Yu, Hai and Deng, Liehua and Lyu, Jun},
	doi = {10.1002/msp2.25},
	journal-iso = {Malignancy Spectrum},
	journal = {Malignancy Spectrum},
	unique-id = {34802682},
	issn = {2770-9140},
	year = {2024},
	eissn = {2770-9140}
}

@article{MTMT:34802726,
	title = {SENTINEL LYMPH NODE BIOPSY IN THE MANAGEMENT OF PATIENTS WITH MALIGNANT MELANOMA},
	url = {https://m2.mtmt.hu/api/publication/34802726},
	author = {Nguyen Canh, Tung and Nguyen Huu, Quang and Nguyen Hong, Son and Nguyen Dinh, Quan and Vu Nguyen, Binh and Le Thanh, Hien and Ta Thi Ha, Phuong and Vu Dinh, Tam and Nguyen Huu, Sau},
	doi = {10.56320/tcdlhvn.42.132},
	journal-iso = {TC DLH VN},
	journal = {Tạp chí Da liễu học Việt Nam},
	volume = {2023},
	unique-id = {34802726},
	issn = {1859-4824},
	abstract = {Objectives: To evaluate the efficacy of sentinel lymph node biopsy in the treatment of malignant melanoma.Materials and Methods: Thirty-two melanoma patients without distant or clinical lymph node metastasis underwent preoperative lymphoscintigraphy using Tc99m and a handheld gamma probe to identify sentinel lymph nodes for biopsy. In cases with detected sentinel lymph node metastasis, the patient may require total complete lymph node dissection, combined with optional systemic therapy. Follow-up was performed to evaluate the efficacy of this procedure.Results: In 32 melanoma patients, the most common site of primary tumors was the extremity, accounting for 90.6%, with a mean Breslow index (thickness of the primary tumor) of 1.84 mm. The incidence of microscopic lymph node metastasis was 34.4%. For cases with no detected sentinel lymph node metastasis, 100% of patients had a stable condition, and no recurrence or metastasis was detected. In 11 cases with occult nodal metastasis: 2 deaths, 4 patients were treated with chemotherapy, and 5 cases without chemotherapy. The mean duration of hospitalization for the group with sentinel lymph node metastasis was greater than that of the group without sentinel lymph node metastasis, 25.1 ± 3.1 days and 13.5 ± 1.3 days, respectively.Conclusion: Our results suggest that sentinel lymph node biopsy is a less invasive technique for melanoma patients with no clinically detectable lymph node and distant metastases. This procedure has shown initial outcomes, but it is necessary to conduct a study with a larger sample size and a longer follow-up time, as well as comparing it with a control group for accurate evaluation.Received 23 June 2023Revised 22 September 2023Accepted 27 November 2023},
	year = {2024},
	pages = {37-44}
}

@article{MTMT:33600344,
	title = {Regression in cutaneous melanoma. histological assessment, immune mechanisms and clinical implications},
	url = {https://m2.mtmt.hu/api/publication/33600344},
	author = {Aivazian, Karina},
	doi = {10.1016/j.pathol.2022.11.005},
	journal-iso = {PATHOLOGY},
	journal = {PATHOLOGY},
	volume = {55},
	unique-id = {33600344},
	issn = {0031-3025},
	abstract = {Tumour regression is an immunologically driven process that results in complete or partial disappearance of tumour cells. This can be observed in histological sections as replacement of tumour cells with fibrosis, angiogenesis, and a variable inflammatory infiltrate. In primary cutaneous melanoma, the prognostic significance of regression has been debated for decades, in part because inconsistent histological criteria are used in prognostication studies. It is broadly accepted that CD8+ T lymphocytes are the primary effectors of the anti-tumour response, but the interplay between melanoma and the immune system is complex, dynamic, and incompletely understood. Sustained progress in unravelling the pathogenesis of melanoma regression has led to the identification of therapeutic targets, culminating in the development of immune checkpoint inhibitors for the management of advanced disease. Modern techniques allow for high-resolution spatial analyses of the tumour microenvironment. Such studies may lead to better understanding of the immune drivers of melanoma regression, thereby facilitating the search for new prognostic and predictive biomarkers to assist clinical decision-making.},
	keywords = {immunology; Prognosis; Biomarkers; pathology; immunotherapy; Regression; TILs; Tumour infiltrating lymphocytes; Primary cutaneous melanoma},
	year = {2023},
	eissn = {1465-3931},
	pages = {227-235}
}

@misc{MTMT:34802683,
	title = {Decision Making in Patients with Initial Positive Deep Margins on Diagnostic Biopsy of Melanoma},
	url = {https://m2.mtmt.hu/api/publication/34802683},
	author = {Ana, Eliza Souza Cunha},
	unique-id = {34802683},
	year = {2023}
}

@article{MTMT:34162530,
	title = {Sentinel lymph node assessment in melanoma: current state and future directions},
	url = {https://m2.mtmt.hu/api/publication/34162530},
	author = {Cheng, TW and Hartsough, E and Giubellino, A},
	doi = {10.1111/his.15011},
	journal-iso = {HISTOPATHOLOGY},
	journal = {HISTOPATHOLOGY},
	volume = {83},
	unique-id = {34162530},
	issn = {0309-0167},
	year = {2023},
	eissn = {1365-2559},
	pages = {669-684}
}

@article{MTMT:34802680,
	title = {Multicentre experience from tertiary skin cancer units on the role of sentinel lymph node biopsy in patients with pT1b melanoma},
	url = {https://m2.mtmt.hu/api/publication/34802680},
	author = {Hughes, Sam and Srenathan, Hareni and Lynch, Magnus and Leeman, Hayley},
	doi = {10.1093/ced/llad450},
	journal-iso = {CLIN EXP DERMATOL},
	journal = {CLINICAL AND EXPERIMENTAL DERMATOLOGY},
	unique-id = {34802680},
	issn = {0307-6938},
	year = {2023},
	eissn = {1365-2230},
	orcid-numbers = {Hughes, Sam/0000-0002-3655-131X}
}

@article{MTMT:34627806,
	title = {Is sentinel lymph node biopsy needed for lentigo maligna melanoma?},
	url = {https://m2.mtmt.hu/api/publication/34627806},
	author = {Kakish, Hanna and Lal, Trisha and Thuener, Jason E. and Bordeaux, Jeremy S. and Mangla, Ankit and Rothermel, Luke D. and Hoehn, Richard S.},
	doi = {10.1002/jso.27543},
	journal-iso = {J SURG ONCOL},
	journal = {JOURNAL OF SURGICAL ONCOLOGY},
	volume = {129},
	unique-id = {34627806},
	issn = {0022-4790},
	keywords = {Sentinel Lymph Node Biopsy; SEER; NCDB; lentigo maligna melanoma; overall and melanoma specific survival},
	year = {2023},
	eissn = {1096-9098},
	pages = {804-812},
	orcid-numbers = {Kakish, Hanna/0000-0002-1282-5443}
}

@article{MTMT:33999789,
	title = {Vemurafenib-cobimetinib in patients with progressive BRAF-mutated metastatic malignant melanoma},
	url = {https://m2.mtmt.hu/api/publication/33999789},
	author = {Mir, Espinosa Y. and Caballero, Aguirrechu I. and García, Gómez R. and Quesada, Peña S. and López, Caballero N. and Soriano, García J.L. and de, la Caridad Osorio M. and Gracia, Medina E.A. and Ortega, Carballosa A. and Arteaga, Hernández E.},
	journal-iso = {REV CUB INVEST BIOMED},
	journal = {REVISTA CUBANA DE INVESTIGACIONES BIOMÉDICAS},
	volume = {42},
	unique-id = {33999789},
	issn = {0864-0300},
	year = {2023},
	eissn = {1561-3011}
}

@article{MTMT:34224287,
	title = {The Impact of Clinical and Histopathological Factors on Disease Progression and Survival in Thick Cutaneous Melanomas},
	url = {https://m2.mtmt.hu/api/publication/34224287},
	author = {Țăpoi, Dana Antonia and Derewicz, Diana and Gheorghișan-Gălățeanu, Ancuța-Augustina and Dumitru, Adrian Vasile and Ciongariu, Ana Maria and Costache, Mariana},
	doi = {10.3390/biomedicines11102616},
	journal-iso = {BIOMEDICINES},
	journal = {BIOMEDICINES},
	volume = {11},
	unique-id = {34224287},
	abstract = {Thick cutaneous melanomas (Breslow depth > 4 mm) are locally advanced tumors, generally associated with poor prognosis. Nevertheless, these tumors sometimes display unpredictable behavior. This study aims to analyze clinical and histopathological features that can influence the prognosis of thick melanomas. This is a retrospective study on 94 thick primary cutaneous melanomas diagnosed between 2012 and 2018 that were followed-up for at least five years to assess disease progression and survival. We evaluated the age, gender, tumor location, histological subtype, Breslow depth, Clark level, resection margins, mitotic index, the presence/absence of ulceration, necrosis, regression, microsatellites, neurotropism, lymphovascular invasion, and the pattern of tumor-infiltrating lymphocytes, and their association with disease progression and survival. By conducting univariate analysis, we found that progression-free survival (PFS) was significantly associated with female gender, the superficial spreading melanoma (SSM) subtype, mitotic index, necrosis, microsatellites, and perineural invasion. Overall survival (OS) was significantly associated with female gender, Breslow depth, SSM subtype, necrosis, microsatellites, and perineural invasion. Through multivariate Cox proportional hazards regression, we found that the only factors associated with PFS were Breslow depth, necrosis, microsatellites, and perineural invasion, while the factors associated with OS were Breslow depth, necrosis, microsatellites, and perineural invasion. Certain histopathological features such as Breslow depth, necrosis, microsatellites, and perineural invasion could explain differences in disease evolution. This is one of the first studies to demonstrate an association between necrosis and perineural invasion and outcomes in patients with thick melanomas. By identifying high-risk patients, personalized therapy can be provided for improved prognosis.},
	year = {2023},
	eissn = {2227-9059},
	orcid-numbers = {Țăpoi, Dana Antonia/0000-0002-5695-9208}
}

@article{MTMT:32784741,
	title = {Predictive Values of Pathological and Clinical Risk Factors for Positivity of Sentinel Lymph Node Biopsy in Thin Melanoma: A Systematic Review and Meta-Analysis},
	url = {https://m2.mtmt.hu/api/publication/32784741},
	author = {Huang, Hanzi and Fu, Ziyao and Ji, Jiang and Huang, Jiuzuo and Long, Xiao},
	doi = {10.3389/fonc.2022.817510},
	journal-iso = {FRONT ONCOL},
	journal = {FRONTIERS IN ONCOLOGY},
	volume = {12},
	unique-id = {32784741},
	issn = {2234-943X},
	year = {2022},
	eissn = {2234-943X}
}

@article{MTMT:32382630,
	title = {Risk factors and patterns of recurrence after sentinel lymph node biopsy for thin melanoma},
	url = {https://m2.mtmt.hu/api/publication/32382630},
	author = {Kim, Daniel and Chu, Stanley and Khan, Ayesha U. and Compres, Elsy V and Zhang, Hui and Gerami, Pedram and Wayne, Jeffrey D.},
	doi = {10.1007/s00403-021-02229-8},
	journal-iso = {ARCH DERMATOL RES},
	journal = {ARCHIVES OF DERMATOLOGICAL RESEARCH},
	volume = {314},
	unique-id = {32382630},
	issn = {0340-3696},
	abstract = {While having a thin melanoma (defined as AJCC 8 T1 stage tumor <= 1.0 mm) with negative sentinel lymph node biopsy (SLNB) provides an excellent prognosis, some patients still develop recurrence and die. To determine risk factors for any recurrence (local/in-transit, nodal, distant) in thin melanoma patients with negative SLNB and assess survival outcomes. Retrospective review of thin melanomas with negative SLNB from 1999 to 2018 was performed. Two hundred and nine patients were identified. Clinicopathologic characteristics of the primary melanoma were collected. Patterns of recurrence for local/in-transit, nodal or distant recurrence and survival outcomes were analyzed. Eighteen patients (8.6%) developed recurrence: 3 (1.9%) local/in-transit, 4 (2.9%) regional/nodal, and 11 (5.3%) distant recurrence during a median follow-up time of 62 months. A multivariate Cox regression model showed that head and neck site (HR 3.52), ulceration (HR 10.8), and mitotic rate (HR 1.39) were significant risk factors for recurrence. Median time to first recurrence was 49 months. Patients with recurrence had a significantly worse 5 year overall survival than those without recurrence (82.2 vs 99.2%). A retrospective single center study and limited sample size. Did not factor in possible false negative SLNBs when calculating hazard ratios. For thin melanoma patients with negative SLNB, heightened surveillance is warranted for those with ulceration, primary tumor location on the head or neck, and elevated mitotic rate.},
	keywords = {SURVIVAL; Prognosis; Oncology; Melanoma; Sentinel Lymph Node Biopsy; Thin melanoma},
	year = {2022},
	eissn = {1432-069X},
	pages = {285-292}
}

@article{MTMT:33447481,
	title = {The EORTC protocol for sentinel lymph node biopsy (SLNB) reveals a high number of nodal nevi and a strong association with nevus-associated melanoma},
	url = {https://m2.mtmt.hu/api/publication/33447481},
	author = {Ricci, Costantino and Dika, Emi and Lambertini, Martina and Ambrosi, Francesca and Chiarucci, Federico and Chillotti, Stefano and Fiorentino, Michelangelo and Fabbri, Erich and Tassone, Daniela and Veronesi, Giulia and Tartari, Federico and Corti, Barbara},
	doi = {10.1016/j.prp.2022.153805},
	journal-iso = {PATHOL RES PRACT},
	journal = {PATHOLOGY RESEARCH AND PRACTICE},
	volume = {233},
	unique-id = {33447481},
	issn = {0344-0338},
	abstract = {Background: The diagnosis of nodal nevi (NN) is challenging as they mimic melanoma metastases (MM), with a detection rate mostly ranging between 1% and 11% in sentinel lymph node biopsy (SLNB). Herein, we assessed the incidence of NN and the association with the clinical-pathological features of primary melanoma, adopting the updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for SLNB. Methods: All cases of paired melanoma and SLNB were retrospectively evaluated (April 2019-May 2020). Appropriate statistical tests were adopted, with significant variables included in the logistic regression model. Results: 81 patients and a total of 186 lymph nodes (LNs) were included. Eleven patients had only NN and 4 had both NN and MM (18.5%); 29 LNs (15.6%) showed at least one NN and 12 (6.5%) showed more than one NN (a total amount of 43 NN was detected). All NN and none MM stained for p16. NN were associated with age < 60 years (p: 0.042), no ulceration (p: 0.025) and nevus-associated melanoma (NAM) (p: 0.018), with this latter being the only predictor at the logistic regression model (p: 0.022). Conclusions: The updated EORTC protocol shows a high number of NN and highlights a strong association with NAM.},
	keywords = {Melanoma; Sentinel Lymph Node Biopsy; Nodal metastases; EORTC protocol; Nodal nevi},
	year = {2022},
	eissn = {1618-0631},
	orcid-numbers = {Chiarucci, Federico/0000-0002-7483-0336; Corti, Barbara/0000-0001-6555-6227}
}

@mastersthesis{MTMT:34802690,
	title = {Analyse prognostischer Faktoren zur Risikoabschätzung einer Lymphknotenmetastasierung nach Sentinellymphonodektomie bei malignen Melanomen mit einer Tumordicke ≤ 1,00 mm und malignen Melanomen mit einer Tumordicke ≥ 3,5 mm. Eine retrospektive Studie},
	url = {https://m2.mtmt.hu/api/publication/34802690},
	author = {Sabine, Röber},
	unique-id = {34802690},
	year = {2022}
}

@article{MTMT:32820597,
	title = {The Use and Technique of Sentinel Node Biopsy for Skin Cancer},
	url = {https://m2.mtmt.hu/api/publication/32820597},
	author = {Upadhyaya, Siddhi N. and Knackstedt, Rebecca W. and Ko, Jennifer S. and Gastman, Brian R.},
	doi = {10.1097/PRS.0000000000009010},
	journal-iso = {PLAST RECONSTR SURG},
	journal = {PLASTIC AND RECONSTRUCTIVE SURGERY},
	volume = {149},
	unique-id = {32820597},
	issn = {0032-1052},
	abstract = {Learning Objectives: After studying this article, the participant should be able to: 1. Understand the indications for and prognostic value of sentinel lymph node biopsy in skin cancer. 2. Learn the advantages and disadvantages of various modalities used alone or in combination when performing sentinel lymph node biopsy. 3. Understand how to perform sentinel lymph node biopsy in skin cancer patients. Summary: Advances in technique used to perform sentinel lymph node biopsy to assess lymph node status have led to increased accuracy of the procedure and improved patient outcomes.},
	keywords = {BREAST-CANCER; indocyanine green; CUTANEOUS MELANOMA; MALIGNANT-MELANOMA; Wide local excision; LYMPH-NODE; MERKEL CELL-CARCINOMA; EARLY-STAGE MELANOMA; ISOSULFAN BLUE-DYE},
	year = {2022},
	eissn = {1529-4242},
	pages = {995e-1008e}
}

@article{MTMT:32501827,
	title = {More sentinel lymph node biopsies for thin melanomas after transition to AJCC 8th edition do not increase positivity rate: A Danish population-based study of 7148 patients},
	url = {https://m2.mtmt.hu/api/publication/32501827},
	author = {Weitemeyer, M.B. and Helvind, N.M. and Brinck, A.M. and Hölmich, L.R. and Chakera, A.H.},
	doi = {10.1002/jso.26723},
	journal-iso = {J SURG ONCOL},
	journal = {JOURNAL OF SURGICAL ONCOLOGY},
	volume = {125},
	unique-id = {32501827},
	issn = {0022-4790},
	abstract = {Background: We evaluated the outcome of sentinel lymph node biopsies (SLNB) in patients with thin melanoma before and after the implementation of AJCC 8th edition (AJCC8) and identified predictors of positive sentinel lymph nodes (+SLN). Methods: Patients diagnosed with T1 melanomas (Breslow thickness ≤1 mm) during 2016–2017 as per AJCC 7th edition (AJCC7) (n = 3414) and 2018–2019 as per AJCC8 (n = 3734) were identified in the Danish Melanoma Database. Results: More SLNBs were performed in the AJCC8 cohort compared to the AJCC7 (22.2% vs. 16.2%, p < 0.001), with no significant difference in +SLN rates (4.7% vs. 6.7%, p = 0.118). In the AJCC7 + SLN subgroup, no melanomas were ulcerated, 94.6% had mitotic rate (MR) ≥ 1, 67.6% were ≥0.8 mm and 32.4% would be T1a according to AJCC8. In the AJCC8 + SLN subgroup, 10.3% were ulcerated, 74.4% had MR≥ 1, 97.4% were ≥0.8 mm and 23.1% would be T1a according to AJCC7. On multivariable analysis younger age and MR ≥ 1 were significant predictors of +SLN. Conclusion: More SLNBs were performed in T1 melanomas after transition to AJCC8 without an increase in +SLN rate. None of the AJCC8 T1b criteria were significant predictors of +SLN. We suggest that mitosis and younger age should be considered as indications for SLNB in thin melanoma. © 2021 Wiley Periodicals LLC.},
	keywords = {Mitosis; cancer staging; ulceration; Lymph node metastasis},
	year = {2022},
	eissn = {1096-9098},
	pages = {498-508}
}

@article{MTMT:32336853,
	title = {Histological regression in melanoma: impact on sentinel lymph node status and survival},
	url = {https://m2.mtmt.hu/api/publication/32336853},
	author = {Aivazian, Karina and Ahmed, Tasnia and El Sharouni, Mary-Ann and Stretch, Jonathan R. and Saw, Robyn P. M. and Spillane, Andrew J. and Shannon, Kerwin F. and Ch'ng, Sydney and Nieweg, Omgo E. and Thompson, John F. and Lo, Serigne N. and Scolyer, Richard A.},
	doi = {10.1038/s41379-021-00870-2},
	journal-iso = {MODERN PATHOL},
	journal = {MODERN PATHOLOGY},
	volume = {34},
	unique-id = {32336853},
	issn = {0893-3952},
	abstract = {Regression in melanoma is an immunological phenomenon that results in partial or complete replacement of the tumor with variably vascular fibrous tissue, often accompanied by pigment-laden macrophages and chronic inflammation. In some cases, tumor-infiltrating lymphocytes (TILs) may represent the earliest phase of this process. The prognostic significance of regression has long been a matter of debate, with inconsistent findings reported in the literature to date. This study sought to determine whether regression in primary cutaneous melanomas predicted sentinel lymph node (SLN) status and survival outcomes in a large cohort of patients managed at a single centre. Clinical and pathological parameters for 8,693 consecutive cases were retrieved. Associations between regression and SLN status, overall survival (OS), melanoma-specific survival (MSS) and recurrence-free survival (RFS) were investigated using logistic and Cox regression. Histological evidence of regression was present in 1958 cases (22.5%). Regression was significantly associated with lower Breslow thickness, lower mitotic rate, and absence of ulceration (p < 0.0001). Multivariable analysis showed that regression in combination with TILs independently predicted a negative SLN biopsy (OR 0.33; 95% C.I. 0.20-0.52; p < 0.0001). Patients whose tumors showed both regression and TILs had the highest 10-year OS (65%, 95% C.I. 59-71%), MSS (85%, 95% C.I. 81-89%), and RFS (60%, 95% C.I. 54-66%). On multivariable analyses, the concurrent presence of regression and TILs independently predicted the lowest risk of death from melanoma (HR 0.69; 95% C.I. 0.51-0.94; p = 0.0003) as well as the lowest rate of disease recurrence (HR 0.71; 95% C.I. 0.58-0.85; p < 0.0001). However, in contrast, in the subgroup analysis of Stage III patients, the presence of regression predicted the lowest OS and RFS, with MSS showing a similar trend. Overall, these findings indicate a prognostically favorable role of regression in primary cutaneous melanoma. However, in Stage III melanoma patients, regression may be a marker of more aggressive disease.},
	year = {2021},
	eissn = {1530-0285},
	pages = {1999-2008},
	orcid-numbers = {Ch'ng, Sydney/0000-0002-4011-1253; Scolyer, Richard A./0000-0002-8991-0013}
}

@article{MTMT:32527768,
	title = {An observational study on the molecular profiling of primary melanomas reveals a progression dependence on mitochondrial activation},
	url = {https://m2.mtmt.hu/api/publication/32527768},
	author = {Gil, J. and Rezeli, M. and Lutz, E.G. and Kim, Y. and Sugihara, Y. and Malm, J. and Semenov, Y.R. and Yu, K.-H. and Nguyen, N. and Wan, G. and Kemény, Lajos Vince and Kárpáti, Sarolta and Németh, I.B. and Marko‐varga, G.},
	doi = {10.3390/cancers13236066},
	journal-iso = {CANCERS},
	journal = {CANCERS},
	volume = {13},
	unique-id = {32527768},
	year = {2021},
	eissn = {2072-6694},
	orcid-numbers = {Kemény, Lajos Vince/0000-0002-8233-1844; Kárpáti, Sarolta/0000-0002-8472-0712}
}

@article{MTMT:31920993,
	title = {Re-evaluation of Sentinel Lymph Node Biopsy for Melanoma},
	url = {https://m2.mtmt.hu/api/publication/31920993},
	author = {Morrison, Steven and Han, Dale},
	doi = {10.1007/s11864-021-00819-2},
	journal-iso = {CURR TREAT OPTION ON},
	journal = {CURRENT TREATMENT OPTIONS IN ONCOLOGY},
	volume = {22},
	unique-id = {31920993},
	issn = {1527-2729},
	abstract = {Opinion statement The vast majority of patients newly diagnosed with melanoma present with clinically localized disease, and sentinel lymph node biopsy (SLNB) is a standard of care in the management of these patients, particularly in intermediate thickness cases, in order to provide important prognostic data. However, SLNB also has an important role in the management of patients with other subtypes of melanoma such as thick melanomas, certain thin melanomas, and specific histologic variants of melanoma such as desmoplastic melanoma. Furthermore, there have been technical advances in the SLNB technique, such as the development of newer radiotracers and use of SPECT/CT, and there is some data to suggest performing a SLNB may be therapeutic. Finally, the management of patients with a positive sentinel lymph node (SLN) has undergone dramatic changes over the past several years based on the results of recent important clinical trials. Treatment options for patients with SLN metastases now include surveillance, completion lymph node dissection, and adjuvant therapy with checkpoint inhibitors and targeted therapy. SLNB continues to play a crucial role in the management of patients with melanoma, allowing for risk stratification, potential regional disease control, and further treatment options for patients with a positive SLN.},
	keywords = {staging; Melanoma; Sentinel Lymph Node Biopsy},
	year = {2021},
	eissn = {1534-6277}
}

@article{MTMT:34802694,
	title = {Прогностические факторы метастазирования в сторожевые лимфатические узлы у больных меланомой различной толщины по классификатору Бреслоу [Predictive Factors for Metastasis of Skin Melanoma of Varying Thickness According to Breslow to Sentinel Lymph Nodes]},
	url = {https://m2.mtmt.hu/api/publication/34802694},
	author = {Nikolaeva, E. A. and Krylov, A. S. and Ryzhkov, A. D. and Abdulova, L. Y. and Bilik, M. E. and Zakharova, T. V. and Baryshnikov, K. A.},
	doi = {10.37174/2587-7593-2021-4-3-18-25},
	journal = {Онкологический журнал: лучевая диагностика, лучевая терапия},
	volume = {4},
	unique-id = {34802694},
	issn = {2587-7593},
	abstract = {Purpose : To evaluate the prognostic factors in patients with Breslow skin melanoma of various thicknesses that affect the incidence of metastases in the signal lymph nodes (SLN).},
	year = {2021},
	pages = {18-25},
	orcid-numbers = {Nikolaeva, E. A./0000-0002-7954-2560; Krylov, A. S./0000-0002-8476-7879; Ryzhkov, A. D./0000-0002-9571-801X; Abdulova, L. Y./0000-0001-6799-1919; Bilik, M. E./0000-0002-2592-685X; Zakharova, T. V./0000-0001-7678-1454; Baryshnikov, K. A./0000-0002-9532-4264}
}

@article{MTMT:32501825,
	title = {Regression is significantly associated with outcomes for patients with melanoma},
	url = {https://m2.mtmt.hu/api/publication/32501825},
	author = {Subramanian, S. and Han, G. and Olson, N. and Leong, S.P. and Kashani-Sabet, M. and White, R.L. and Zager, J.S. and Sondak, V.K. and Messina, J.L. and Pockaj, B. and Kosiorek, H.E. and Vetto, J. and Fowler, G. and Schneebaum, S. and Han, D.},
	doi = {10.1016/j.surg.2021.05.010},
	journal-iso = {SURGERY (UNITED STATES)},
	journal = {SURGERY},
	volume = {170},
	unique-id = {32501825},
	issn = {0039-6060},
	abstract = {Background: The prognostic significance of regression in melanoma is debated. We present a large multicenter study correlating regression with sentinel lymph node metastasis and melanoma-specific survival. Methods: The Sentinel Lymph Node Working Group database was reviewed from 1993 to 2018. Patients with known regression and sentinel lymph node status were included. Clinicopathologic factors were correlated with regression, sentinel lymph node status, and melanoma-specific survival. Results: There were 4,790 patients; median follow-up was 39.6 months. Regression was present in 1,081 (22.6%) cases, and 798 (16.7%) patients had sentinel lymph node metastases. On multivariable analysis, male sex, truncal tumors, and decreasing thickness were significantly associated with regression (P < .05), whereas head/neck or leg tumors had lower rates of regression (P < .05). Regression was significantly correlated with a decreased risk of sentinel lymph node disease on multivariable analysis (odds ratio 0.68, 95% confidence interval 0.54–0.85; P = .0008). Multivariable analysis also showed that increasing age, male sex, increasing thickness, ulceration, lymphovascular invasion, microsatellitosis, and sentinel lymph node metastasis were significantly (P < .05) associated with worse melanoma-specific survival, while regression was significantly associated with better melanoma-specific survival (hazard ratio 0.75, 95% confidence interval 0.57–0.99; P = .043). Conclusion: This large study shows that regression is significantly associated with better outcomes in patients with melanoma and is correlated with a lower risk of sentinel lymph node metastasis and a better melanoma-specific survival. © 2021 Elsevier Inc.},
	year = {2021},
	pages = {1487-1494}
}

@article{MTMT:32501826,
	title = {Integrating 31-gene expression profiling with clinicopathologic features to optimize cutaneous melanoma sentinel lymph node metastasis prediction},
	url = {https://m2.mtmt.hu/api/publication/32501826},
	author = {Whitman, E.D. and Koshenkov, V.P. and Gastman, B.R. and Lewis, D. and Hsueh, E.C. and Pak, H. and Trezona, T.P. and Davidson, R.S. and McPhee, M. and Michael, Guenther J. and Toomey, P. and Smith, F.O. and Beitsch, P.D. and Lewis, J.M. and Ward, A. and Young, S.E. and Shah, P.K. and Quick, A.P. and Martin, B.J. and Zolochevska, O. and Covington, K.R. and Monzon, F.A. and Goldberg, M.S. and Cook, R.W. and Fleming, M.D. and Hyams, D.M. and Vetto, J.T.},
	doi = {10.1200/PO.21.00162},
	journal-iso = {JCO PRECIS ONCOL},
	journal = {JCO PRECISION ONCOLOGY},
	volume = {5},
	unique-id = {32501826},
	abstract = {PURPOSE National guidelines recommend sentinel lymph node biopsy (SLNB) be offered to patients with . 10% likelihood of sentinel lymph node (SLN) positivity. On the other hand, guidelines do not recommend SLNB for patients with T1a tumors without high-risk features who have, 5% likelihood of a positive SLN. However, the decision to perform SLNB is less certain for patients with higher-risk T1 melanomas in which a positive node is expected 5%-10% of the time. We hypothesized that integrating clinicopathologic features with the 31-gene expression profile (31-GEP) score using advanced artificial intelligence techniques would provide more precise SLN risk prediction. METHODS An integrated 31-GEP (i31-GEP) neural network algorithm incorporating clinicopathologic features with the continuous 31-GEP score was developed using a previously reported patient cohort (n = 1,398) and validated using an independent cohort (n = 1,674). RESULTS Compared with other covariates in the i31-GEP, the continuous 31-GEP score had the largest likelihood ratio (G2 = 91.3, P, .001) for predicting SLN positivity. The i31-GEP demonstrated high concordance between predicted and observed SLN positivity rates (linear regression slope = 0.999). The i31-GEP increased the percentage of patients with T1-T4 tumors predicted to have, 5% SLN-positive likelihood from 8.5% to 27.7% with a negative predictive value of 98%. Importantly, for patients with T1 tumors originally classified with a likelihood of SLN positivity of 5%-10%, the i31-GEP reclassified 63% of cases as having, 5% or . 10% likelihood of positive SLN, for a more precise, personalized, and clinically actionable SLN-positive likelihood estimate. CONCLUSION These data suggest the i31-GEP could reduce the number of SLNBs performed by identifying patients with likelihood under the 5% threshold for performance of SLNB and improve the yield of positive SLNBs by identifying patients more likely to have a positive SLNB. © 2021 by American Society of Clinical Oncology},
	year = {2021},
	eissn = {2473-4284},
	pages = {1466-1479}
}